With Huang Medicine: SAFFRON study completed patient enrollment.

According to an announcement by Huang Pharmaceuticals, the company announced that the SAFFRON global Phase III study for the combination therapy of voriorsh and tairisha for the treatment of specific lung cancer patients with MET overexpression and/or amplification after treatment with tairisha has completed patient enrollment. The SAFFRON study aims to evaluate the effectiveness of this combination therapy for the treatment of locally advanced or metastatic non-small cell lung cancer patients, with the final patient being enrolled on October 31, 2025. The primary endpoint of the study is progression-free survival, with other endpoints including overall survival, objective response rate, etc. The study included a total of 338 patients, with top-line results expected to be announced in the first half of 2026.